Nanomedicine-Enabled/Augmented Cell Pyroptosis for Efficient Tumor Nanotherapy

Area of Science:

• Oncology
• Nanotechnology
• Immunology

Background:

• Malignant tumors, particularly apoptosis-resistant types, necessitate novel therapeutic strategies.
• Pyroptosis, a pro-inflammatory programmed cell death (PCD), offers a promising avenue by remodeling the tumor immune microenvironment.
• Nanotechnology provides tools to potentiate pyroptosis for improved cancer treatment.

Purpose of the Study:

• To review recent advancements in nanomedicine-driven pyroptosis for cancer therapy.
• To highlight nanomedicine strategies that specifically induce pyroptosis.
• To discuss the potential of nanomedicines in generating next-generation therapeutics.

Main Methods:

• Review of current literature on nanomedicine and pyroptosis in cancer research.
• Analysis of strategies employing nanotechnology to induce or augment pyroptosis.
• Discussion of how pyroptosis influences the tumor immune microenvironment.

Main Results:

• Nanomedicine effectively potentiates, enables, and augments pyroptosis for enhanced cancer therapy.
• Pyroptosis converts "cold" tumor microenvironments into immunogenic "hot" ones.
• Specific pyroptosis induction via nanomedicine is a key strategy for next-generation therapeutics.

Conclusions:

• Nanomedicine-enabled pyroptosis significantly enhances anti-cancer therapeutic efficacy and specificity.
• Inducing pyroptotic cell death through bioactive nanomedicines can accelerate clinical translation.
• This approach holds promise for overcoming resistance to conventional cancer therapies.